Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation

Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation

Abstract The molecular chaperone Clusterin (CLU) impacts the amyloid pathway in Alzheimer’s disease (AD) but its role in tau pathology is unknown. We observed CLU co-localization with tau aggregates in AD and primary tauopathies and CLU levels were upregulated in response to tau accumulation. To fur...

Full description

Bibliographic Details
Main Authors: Aleksandra M. Wojtas, Yari Carlomagno, Jonathon P. Sens, Silvia S. Kang, Tanner D. Jensen, Aishe Kurti, Kelsey E. Baker, Taylor J. Berry, Virginia R. Phillips, Monica Casey Castanedes, Ayesha Awan, Michael DeTure, Cristhoper H. Fernandez De Castro, Ariston L. Librero, Mei Yue, Lillian Daughrity, Karen R. Jansen-West, Casey N. Cook, Dennis W. Dickson, Leonard Petrucelli, John D. Fryer
Format: Article
Language:English
Published: BMC 2020-12-01
Series:Acta Neuropathologica Communications
Subjects:
Clusterin
Alzheimer’s disease
Tauopathy
Tau
Online Access:https://doi.org/10.1186/s40478-020-01079-1

Internet

https://doi.org/10.1186/s40478-020-01079-1

Similar Items